NC
IRWD icon

nVerses Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History

nVerses Capital’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-32,554
Closed -$114K – 425
2026
Q1 		$114K Buy
+32,554
New +$133K 0.1% 324

Other funds holding IRWD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

nVerses Capital's IRWD Position: Q2 2026 in Review

nVerses Capital sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2026, closing a stake of 32,554 shares — an estimated $114K sold.

nVerses Capital first reported a position in IRWD in Q1 2026 and held it in 1 quarter. The position peaked at $114K in Q1 2026. 160 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

  • nVerses Capital reported no remaining Ironwood Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • nVerses Capital sold 32,554 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $114K.
  • nVerses Capital first reported a position in Ironwood Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • nVerses Capital's Ironwood Pharmaceuticals position peaked at $114K in Q1 2026.
  • 160 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.